United Therapeutics refiles Remodulin NDA
This article was originally published in Pharmaceutical Approvals Monthly
FDA Cardiovascular and Renal Drugs Advisory Committee recommends approval of United Therapeutics' pulmonary hypertension therapy Remodulin Aug. 9. The company refiled the Remodulin NDA, which was withdrawn by the firm in advance of the July 16 user fee date, on the same day. Though FDA has six months to review the submission, the firm expects a decision more quickly
You may also be interested in...
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far.
US Regulatory Roundup, February 2021: QA/RA Predictions, FDA Warning Letter Stats, PMA Case Study, And More
Quality and regulatory predictions for 2021, a count of 2020 US FDA enforcement missives, a premarket approval case study for a novel prosthetic, and more topped our list of most-read Medtech Insight articles in February.
Locke Lord senior counsel Sharon Blinkoff shares perspective from her experience defending smaller cosmetics companies against US class action plaintiff demands and litigation.